Coarctation of the aorta is an important rare cause of treatable hypertension and is found in 0.2% of hypertensive adults. The pathogenesis of hypertension is a combination of mechanical obstruction at the site of coarctation and a generalised vasoconstrictor mechanism, thought to involve the renin-angiotensin and/or sympathetic nervous system.
Most patients who survive infancy reach adulthood, although symptoms may not appear until 20 to 30 years of age. In untreated patients, death occurs in the mid-30s. The obstruction should therefore be corrected in early childhood, usually by surgery, to reduce the incidence of complications such as congestive heart failure, endocarditis and stroke. Since the early 1980s percutaneous transluminal balloon dilatation of the coarctation has been used as an alternative treatment method, initially in patients with restenosis after surgical correction and in neonatal age groups. [1] [2] [3] Good clinical results with low complication rates have resulted in the extension of balloon dilatation to treat aortic coarctation in most patients, including native coarctation in adults, provided that the angiographic morphology is suitable. 4 Successful procedures are defined by a 30% increase in the diameter of the treated segment and at least a 50% reduction in the associated pressure gradient. Technical success rates range between 85-90%, with a complication rate between 3-7%.
